Schroder Investment Management Group Acquires 146,403 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Schroder Investment Management Group boosted its holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 118.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 270,336 shares of the company’s stock after acquiring an additional 146,403 shares during the quarter. Schroder Investment Management Group’s holdings in EyePoint Pharmaceuticals were worth $1,898,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Geode Capital Management LLC raised its position in EyePoint Pharmaceuticals by 16.1% in the 3rd quarter. Geode Capital Management LLC now owns 1,199,056 shares of the company’s stock valued at $9,583,000 after buying an additional 166,699 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of EyePoint Pharmaceuticals by 5.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 142,763 shares of the company’s stock valued at $1,141,000 after purchasing an additional 7,967 shares during the last quarter. Barclays PLC lifted its position in shares of EyePoint Pharmaceuticals by 410.4% during the third quarter. Barclays PLC now owns 245,045 shares of the company’s stock valued at $1,959,000 after purchasing an additional 197,033 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in EyePoint Pharmaceuticals by 1,171.3% during the third quarter. JPMorgan Chase & Co. now owns 371,758 shares of the company’s stock worth $2,970,000 after purchasing an additional 342,516 shares during the last quarter. Finally, Franklin Resources Inc. grew its position in EyePoint Pharmaceuticals by 9.9% in the 3rd quarter. Franklin Resources Inc. now owns 4,012,048 shares of the company’s stock worth $32,056,000 after purchasing an additional 362,399 shares in the last quarter. Institutional investors and hedge funds own 99.41% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on EYPT. StockNews.com upgraded EyePoint Pharmaceuticals to a “sell” rating in a research note on Friday, March 14th. Citigroup began coverage on EyePoint Pharmaceuticals in a research note on Tuesday, January 7th. They issued a “buy” rating and a $33.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $22.00 price target on shares of EyePoint Pharmaceuticals in a report on Thursday, March 6th. Finally, Chardan Capital restated a “buy” rating and set a $33.00 price objective on shares of EyePoint Pharmaceuticals in a report on Thursday, March 6th. One analyst has rated the stock with a sell rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat, EyePoint Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $26.63.

EyePoint Pharmaceuticals Trading Down 7.6 %

Shares of EYPT stock opened at $4.61 on Monday. The firm’s 50 day moving average is $6.47 and its 200 day moving average is $8.09. The stock has a market capitalization of $316.84 million, a P/E ratio of -2.31 and a beta of 1.39. EyePoint Pharmaceuticals, Inc. has a 12 month low of $4.51 and a 12 month high of $23.65.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last posted its quarterly earnings results on Wednesday, March 5th. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.10). EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%. The company had revenue of $11.60 million during the quarter, compared to the consensus estimate of $11.02 million. On average, equities analysts predict that EyePoint Pharmaceuticals, Inc. will post -2.13 EPS for the current year.

EyePoint Pharmaceuticals Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.